Literature DB >> 31176682

CD95/Fas and metastatic disease: What does not kill you makes you stronger.

Jean Philippe Guégan1, Christophe Ginestier2, Emmanuelle Charafe-Jauffret2, Thomas Ducret3, Jean-François Quignard3, Pierre Vacher4, Patrick Legembre5.   

Abstract

CD95 (also known as Fas) is the prototype of death receptors; however, evidence suggests that this receptor mainly implements non-apoptotic signaling pathways such as NF-κB, MAPK, and PI3K that are involved in cell migration, differentiation, survival, and cytokine secretion. At least two different forms of CD95 L exist. The multi-aggregated transmembrane ligand (m-CD95 L) is cleaved by metalloproteases to release a homotrimeric soluble ligand (s-CD95 L). Unlike m-CD95 L, the interaction between s-CD95 L and its receptor CD95 fails to trigger apoptosis, but instead promotes calcium-dependent cell migration, which contributes to the accumulation of inflammatory Th17 cells in damaged organs of lupus patients and favors cancer cell invasiveness. Novel inhibitors targeting the pro-inflammatory roles of CD95/CD95 L may provide attractive therapeutic options for patients with chronic inflammatory disorders or cancer. This review discusses the roles of the CD95/CD95 L pair in cell migration and metastasis.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Calcium; Cytoskeleton; Migration; TNF

Year:  2019        PMID: 31176682     DOI: 10.1016/j.semcancer.2019.06.004

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  9 in total

Review 1.  Fas/CD95 Signaling Pathway in Damage-Associated Molecular Pattern (DAMP)-Sensing Receptors.

Authors:  Gael Galli; Pierre Vacher; Bernhard Ryffel; Patrick Blanco; Patrick Legembre
Journal:  Cells       Date:  2022-04-24       Impact factor: 7.666

2.  Celecoxib as an adjuvant to chemotherapy for patients with metastatic colorectal cancer: A randomized controlled clinical study.

Authors:  Tarek M Mostafa; Mohamed A Alm El-Din; Amira R Rashdan
Journal:  Saudi Med J       Date:  2022-01       Impact factor: 1.422

Review 3.  The Role of TRAIL/DRs in the Modulation of Immune Cells and Responses.

Authors:  Duygu Sag; Zeynep Ozge Ayyildiz; Sinem Gunalp; Gerhard Wingender
Journal:  Cancers (Basel)       Date:  2019-09-30       Impact factor: 6.639

4.  CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells.

Authors:  Abdul S Qadir; Jean Philippe Guégan; Christophe Ginestier; Assia Chaibi; Alban Bessede; Emmanuelle Charafe-Jauffret; Manon Macario; Vincent Lavoué; Thibault de la Motte Rouge; Calvin Law; Jacob Vilker; Hongbin Wang; Emily Stroup; Matthew J Schipma; Bryan Bridgeman; Andrea E Murmann; Zhe Ji; Patrick Legembre; Marcus E Peter
Journal:  iScience       Date:  2021-10-29

Review 5.  Shuttling of cellular proteins between the plasma membrane and nucleus (Review).

Authors:  Hua-Chuan Zheng; Hua-Mao Jiang
Journal:  Mol Med Rep       Date:  2021-11-15       Impact factor: 2.952

6.  Different methods of detaching adherent cells and their effects on the cell surface expression of Fas receptor and Fas ligand.

Authors:  Ting-Yu Lai; Jerry Cao; Pu Ou-Yang; Ching-Yi Tsai; Chih-Wen Lin; Chien-Chia Chen; Meng-Kun Tsai; Chih-Yuan Lee
Journal:  Sci Rep       Date:  2022-04-05       Impact factor: 4.379

7.  Downregulation of Three Immune-Specific Core Genes and the Regulatory Pathways in Children and Adult Friedreich's Ataxia: A Comprehensive Analysis Based on Microarray.

Authors:  Lichun Liu; Yongxing Lai; Zhidong Zhan; Qingxian Fu; Yuelian Jiang
Journal:  Front Neurol       Date:  2022-02-14       Impact factor: 4.003

Review 8.  Altered pathways and targeted therapy in double hit lymphoma.

Authors:  Yuxin Zhuang; Jinxin Che; Meijuan Wu; Yu Guo; Yongjin Xu; Xiaowu Dong; Haiyan Yang
Journal:  J Hematol Oncol       Date:  2022-03-18       Impact factor: 17.388

9.  Development and Validation of a Novel Survival Model for Cutaneous Melanoma Based on Necroptosis-Related Genes.

Authors:  Zehao Niu; Xin Wang; Yujian Xu; Yan Li; Xiaojing Gong; Quan Zeng; Biao Zhang; Jiafei Xi; Xuetao Pei; Wen Yue; Yan Han
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.